ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

186
Analysis
Health CareChina
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
bearishYishengBio
06 Apr 2021 10:54

YishengBio (依生生物) Pre-IPO: Need a Faithful Bet in PIKA

YishengBio is a China-based biopharmaceutical company with a focus of developing PIKA based technology for vaccine and oncology. We like the...

Logo
274 Views
Share
20 Mar 2021 23:59

Quiddity Weekly H/A: Consumer Strong, Spreads Narrowing Masks A-Share Weakness

The move in H/A spreads was 96bp this week. The strength in spreads masks some A-share weakness in the big and liquid names. Quiddity long/short...

Logo
378 Views
Share
14 Mar 2021 13:12

Quiddity Weekly H/A: Energy Up, Spreads Wider, Pharmas Down Spreads Narrower

Spread momentum continues unabated. Of note, CanSino's vaccine approval is getting no friends as the stock is down nearly 25% in 2 weeks and 29% in...

Logo
184 Views
Share
07 Mar 2021 21:42

Quiddity Weekly H/A: Financials Outpace Everything Else: Marketwide 87% Upside to A-Share Parity

H/A spreads were largely unchanged on the week but more widened than narrowed. Financials was the only sector narrower on the whole. With average...

Logo
231 Views
Share
03 Mar 2021 09:28

CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?

This article analyzed CanSino's core technology platforms, key products in the pipeline, insights on the products and core competitiveness and also...

Logo
299 Views
Share
x